Aclarion announces publication of seminal nociscan cost-effectiveness analysis

Independent cost-effectiveness analysis concludes nociscan is effective and less costly compared to provocative discography conclusions illustrate nociscan saves $1,712 per patient and improves surgical success by 10% broomfield, colo., april 21, 2025 (globe newswire) -- aclarion, inc., (“aclarion” or the “company”) (nasdaq: acon, aconw), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (ai) algorithms to help physicians identify the location of chronic low back pain, announced today the publication of a peer-reviewed article in clinicoeconomics and outcomes research titled "the comparison of cost-effectiveness between magnetic resonance spectroscopy and provocative discography in the identification of chronic low back pain surgery candidates.
ACON Ratings Summary
ACON Quant Ranking